Search
Displaying 101–110 of 694 for “retinal diseases”
-
AGTC Leverages Funding from the Foundation to Move Promising Treatments into Clinical Trials
Research NewsCompany Builds on FFB’s Initial Investment to Garner $265 Million in Therapy Development Funding
-
Nobel Prize Winners Have Big Impact on Emerging Retinal Treatments
Research NewsThe 2012 Nobel Medicine prize winners are having an enormous impact on sight-saving retinal research.
-
Pixium Vision Reports Progress in Development of Two Advanced Bionic Retina Systems
Research NewsBoth approaches show strong, near-term potential for providing meaningful vision to people who are otherwise blind from retinal diseases such as retinitis pigmentosa and age-related macular degeneration (AMD).
-
A Leap Forward: Spark Therapeutics Seeks FDA Approval for its Vision-Restoring Gene Therapy
Research NewsA Leap Forward: Spark Therapeutics Seeks FDA Approval for its Vision-Restoring Gene Therapy
-
Foundation’s Reach Inspires Partnership for Nixon Family
Beacon StoriesAfter Janine’s diagnosis of an IRD caused by a mutation of the PRPH2 gene, she and her husband set out to learn and help all they could. So they started working with the Foundation Fighting Blindness and have launched the ‘PRPH2 and Associated Retinal Degenerations Program.’
-
Passionate Professional Outreach Volunteer Helping Newly Diagnosed
Beacon StoriesJim has always been avid about giving back to others, even after he was diagnosed with retinitis pigmentosa. And in the last few years, he’s begun working with the Foundation to help eye care professionals in the Cincinnati and Northern Kentucky area provide vital resources for their patients with retinal diseases.
-
The RD Fund Announces Ocuphire Pharma’s Acquisition of Opus Genetics
In the PressThe resulting company will operate under the name Opus Genetics and the Nasdaq ticker symbol (IRD).
-
Total Blindness and Non-24 Sleep Disorder
Research NewsNon-24 is a very rare condition affecting many (but not all) people who are totally blind and have absolutely no light perception. Their circadian clocks become out of sync as a result.
-
Ophthotech Launching Human Study of Emerging Therapy for Stargardt Disease
Research NewsOphthotech, a biopharmaceutical company developing therapies for eye diseases, has enrolled the first patient in its Phase 2b clinical trial of Zimura® for people with Stargardt disease caused by mutations in the gene ABCA4.
-
ARVO 2015 Highlight: The National Eye Institute Invests $4 Million in Audacious-Goals Research
Research NewsThe mission of the program—to regenerate the neurons and neural connections in the eye and visual system—is synonymous with the Foundation’s mission to eradicate retinal diseases.
